• Supported development of the Zolgensma gene therapy scientific narrative, Scientific Communication Platform (SCP), and SMA Clinical Evidence Resource Pack• Publications experience preparing congress abstracts posters and presentations, manuscript development and submissions, synthesizing feedback from internal and external authors• Global Medical Communications supporting symposia, congresses, Medical Q&A & scientific messaging• Primary Medical reviewer on Product Review Committee PRC for Product Launch of Zolgensma for SMA• Developed over 100 data-on-file documents to verify data from completed and ongoing open label clinical trials (STR1VE-US, STR1VE-EU, SPR1NT, START, STRONG, LT-001, LT-002)• Highly knowledgeable of OAV-101 Clinical Program from a Medical Affairs Perspective• Worked collaboratively and cross functionally with Marketing, Training, Corporate Communications and fellow reviewers and project owners to align on a path forward for content

• Medical Communications Medical reviewer: Commercial gene therapy product launch• Medical reviewer in the CMLR function reviewing Immunology content for Commercial, Medical, and International through Veeva and Zinc (Shire)• Managed the redevelopment of over a dozen field facing TA and product slide decks for Immunology Global Medical Affairs (Baxalta)• Supporting commercial messaging of new clinical data for an approved ophthalmology medication (Genentech)• Assessment of an infusion pump for use in an ambulatory setting• Facilitated expert interviews to understand products in development for psoriasis (Janssen)

• Provided Competitive Intelligence (CI) for Astellas:o Proposed plan for the incentive compensation for a client promoting 2 products for same indicationo Completed planning assessment of workflow and work capacity of competitive CI function making recommendations to secure additional resources for CI function• Created drug product competitive landscape assessments of all products in clinical development for NHL, AML, NSCLC and prostate cancer including timelines predicting product launches until 2020 • Developed launch starter kit, launch plan, and background presentation for antifungal product• Facilitated workshop to create new strategies and approaches to treat nociceptive and neuropathic pain (Teva)

Strategic Consulting including: • Provided commercial and new product evaluations of small molecules and biologics for pharmaceutical, and bio-pharmaceutical companies, for example: o Provided competitive intelligence about biosimilars and drug delivery devices for Amgen o Created business plan for dermatology franchise concept o Developed probing questions for VC firm considering investing in biotech company• Produced revenue forecasts for products and MS Excel-based financial modeling• Prepared compelling reports and presentations detailing market research and development efforts• Skilled at interviewing key opinion leaders, physicians, nurses and other health care professionals

• Played an active role in commercial and new product evaluations of small molecules, biologics, and medical devices for hedge funds, pharmaceutical, and bio-pharmaceutical companies• Devised a no-go recommendation for a company’s planned medical device acquisition after revealing poor physician acceptance and minimal medical need• Provided valuations of large, multi-national drug product portfolios, which proved instrumental in securing private equity funding that infused business expansion• Crafted a positioning strategy for a next generation drug that achieved clear differentiation from others in the same class• Conducted primary market research as a liaison to over 200 prescribing physicians and Key Opinion Leaders• Produced revenue forecasts and modeling• Determined product opportunity forecasts which projected peak year of sales for 20 products• Prepared compelling reports and presentations detailing market research and development efforts

• Evaluated commercial opportunities within 4 immunology therapeutic areas, including chronic obstructive pulmonary disease, rheumatoid arthritis, psoriasis, and Crohn’s disease• Examined market potential of products in development as compared to approved products• Conducted competitive analysis and reviewed products with Key Opinion Leaders to gain insight• Primary author responsible for developing 4 presentations and white papers for senior management• Received executive approval for product recommendations and transition to business development• Utilized IMS, IDdb3, Citeline, Decision Resources, Trial Trove, Tandem Cancer Audit and Prous Science Integrity databases

• Stanford Graduate School of Business: Completed four MBA courses, including Business Plan Development, Innovation in Neurologic Disease, Ethics in the Pharmaceutical Industry, Careers in Life Science.• Research Highlights: Studied B cell development using a mouse model. Discovered a key gene regulator involved in cell division relevant to lymphoma with implications for new treatments.

• Co-developed a science consultation for a business plan that was crucial to the launch of ConfometRx Inc., a start-up company that originated at Stanford University• Worked closely with the chairman of Nektar Therapeutics to commercialize a technology for the production of GPCR protein, the richest source of drug targets. Subsequently led to an agreement with Medarex Inc. as the company's first client

• Developed an innovative medical device concept to treat brain strokes as a partner to a four-person interdisciplinary team which won an entrepreneurial award for this effort.• The technology combined a shape memory polymer with a bioabsorbable stent• Called the Memostent Project our idea was judged the most likely to succeed by Silicon Valley Venture Capitalists

• Managed a $1 million dollar annual operating budget for an 84-unit apartment building• Generated a budget surplus over four years consecutively and significantly increased investment returns on reserve funds• Doubled the replacement reserve contribution to $50,000 per year and limited rent increases due to cost-savings measures via contracts with utilities providers

• Optimised and performed cell proliferation experiments with rainbow trout cell lines, published• Studied the effect of glutamine and mitogens on mitogenesis

• Assisted in the development of a diagnostic for carcinogenesis, a precursor to gene chips• Co-designed a diagnostic test for rapid determination of chemical carcinogenesis• Gained skills in animal cell culture, mRNA purification, reverse transcription, dot blots, Northern blots, plasmid extraction, restriction enzyme digestion, and use of radioisotopes• Published

• Actively participated in development of a point-of-care diagnostic testing product for heart attack, which accelerated testing and provided immediate data without waiting for laboratory results• Purified recombinant cardiac proteins grown from bacterial cell culture. Utilized ion exchange chromatography, ultrafiltration, dialysis, Bradford protein assay, and Western blotting• Determined the isoelectric point of recombinant proteins, such as myosin light chain

• Identified sources, accumulation, distribution, and degradation of mixed function oxidase (p450) inducing compounds in pulp mill effluent and their effect on rainbow trout

• Analysed sewage and industrial effluent for ammonia, BOD, suspended solids, oil and grease• Assessed the impact of Cryptosporidium, a waterborne parasite, on the local water supply

• Prepared mineral samples for analytical analysis monitoring smelting efficiency• Analysed mineral samples using inductively coupled and direct current plasma spectroscopy

• Produced evacuated blood collection tubes, established operating protocols for new products• Trained personnel in assembly line operation and implemented changes improving productivity